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Abstract Activity of dalbavancin against methicillin-
resistant Staphylococcus aureus (MRSA) and methicillin-
resistant Staphylococcus epidermidis (MRSE) in biofilm was
investigated and the microbicidal biofilm concentrations
(MBC) were determined. Biofilms obtained from ten MRSA
and tenMRSE bloodstream isolates, collected from patients in
the General Hospital of Vienna between 2012 and 2015, were
incubated with dalbavancin in trypticase soy broth (TSB) in
serial dilution from 0.0625 mg/l to 256 mg/l using a microtiter
plate biofilm model. The plates were incubated for 24 h at 37 °
C and 50% humidity. Biofilms were fixed with 2.5% glutar-
aldehyde and stained with crystal violet. Subsequently the
optical density (OD620) was used to measure the MBC,
defined as the concentration of dalbavancin leading to a
50% reduction of biofilm. MBC for MRSA was 1 mg/l–
4 mg/l (minimal inhibitory concentrations (MIC)
0.0312 mg/l–0.064 mg/l). MBC for MRSE was 2 mg/l–
16 mg/l (MIC 0.023 mg/l–0.0625 mg/l). Dalbavancin
successfully reduced MRSA and MRSE in biofilms,
and therefore provides a promising option for the treat-
ment of biofilm-associated infections.
Introduction
Medical devices, such as intravenous catheters, prosthetic
heart valves, and vascular or joint prostheses, have contributed
to reducing morbidity and mortality for numerous patients
every year [1]. However, they are fraught with the risk of
leading to surface-associated infections through formation of
bacterial or fungal biofilms [1]. Although explantation of the
infected device is the preferred treatment option, in some cases
removal is not feasible due to absolute necessity of the im-
plant, difficulty of surgery, or inoperability of the patient, to
mention only a few reasons. Another problem with bacterial
biofilm infections is that they are often resistant to antibiotic
therapy despite the sensitivity of the single planktonic organ-
isms to the antibiotic [1, 2]. Staphylococcus aureus (S. aureus)
and Staphylococcus epidermidis (S. epidermidis) are among
the most common pathogens associated with surface-
associated infections [1–3]. Unfortunately, methicillin-
resistant S. aureus (MRSA) and methicillin-resistant
S. epidermidis (MRSE) are also very prevalent nosocomi-
al pathogens, often responsible for medical device infec-
tions [4, 5]. Dalbavancin is a novel semisynthetic
lipoglycopeptide with unique pharmacokinetic properties
allowing weekly dosing [6]. Recent data indicate that
dalbavancin may have antimicrobial potential against pro-
karyotic biofilms [7, 8]. Furthermore, it has a broad anti-
microbial gram-positive spectrum (>6,000 g-positive
isolates) including activity against methicillin-resistant
staphylococci, which show remarkable susceptibility to
dalbavancin (e.g., MIC-range S. aureus ≤ 0.015–0.25 mg/
l; MIC-range coagulase-negative staphylococci ≤ 0.015–
0.25 mg/l) [9]. Its high efficacy paired with its dosage
regimen provides the opportunity to treat patients with
gram-positive infections, normally requiring inpatient an-
tibiotics, as outpatients. The objective of this study was to
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investigate the in-vitro activity of dalbavancin against
MRSA and MRSE isolates.
Methods
In our study, we used ten MRSA and ten MRSE blood-
stream isolates acquired from patients treated in the
General Hospital of Vienna between 2012 and 2015.
Preparation of sterile stock solutions of dalbavancin
(Xydalba®, Durata Therapeutics International B.V. ®,
Chicago, IL, USA) was performed in trypticase soy broth
(TSB) (Oxoid®, Hampshire, UK). MICs were determined
using the microdilution method and were confirmed with
E-tests according to the procedures outlined by the Clinical
and Laboratory Standards Institute (CLSI). A modified
Christensen method was used for biofilm formation, with
the strains grown overnight on Columbia-blood-agar
(BioMerieux®, Marcy-l’Étoile, France) [10]. Twenty ml
of TSB was then inoculated with a large loop of each strain
and shaken at 90–100 rpm in a brood chamber at 36 °C and
50% humidity for 24 h. The bacterial suspensions were
diluted 1:100 in TSB, equivalent to a colony count of
107 CFU/ml, and incubated on a shaker with 90–100 rpm
in the same brood chamber for 4 h. Then, 200 μl aliquots
of bacterial solutions were placed into 84 wells of a 96-
well polystyrene flat-bottomed microtiter plate (Cellstar®,
greiner bio-one®, Frickenhausen, Germany). The remain-
ing 12 wells served as negative TSB-only controls. After
24 h of incubation, media and planktonic cells were re-
moved and 200 μl/well dalbavancin dissolved in TSB in
serial dilution (0.0625 mg/l to 256 mg/l) was placed in four
wells for each concentration. Twelve wells formerly incu-
bated with bacteria were filled with 200 μl TSB only and
served as positive controls; 12 wells with only TSB served
as negative controls. After another 24 h in the brood cham-
ber, the wells were emptied via deflection, washed with
phosphate buffered saline (PBS), fixed with 150 μl 2.5%
glutaraldehyde (Glutaraldehyde solution Grade II, 25%,
Sigma–Aldrich®, St. Louis, MO, USA), diluted 1 to 10
in Aqua bidestillata for 15 min and dried at 60 ° C for
30 min. The dried biofilms were stained with 150 μl crystal
violet (Merck KGaA®, Darmstadt, Germany) for 5 min
and washed with PBS: 150 μl 33% acetic acid (AnalaR
Normapur, Prolabo®, VWR International®, USA) was
put in each well to improve optical density for quantifica-
tion of biofilm with a BEP II-photometer (Zenyth 340st,
Anthos Labtec BV®, Heerhugowaard, Netherlands). The
optical density was measured at 405 nm, with the back-
ground measured at 620 nm. The MBC was considered to
be the concentration of dalbavancin, which led to a 50%
reduction in optical density.
Results
For planktonic cells, the MIC of dalbavancin ranged from
0.032 mg/l to 0.064 mg/l for MRSA and from 0.023 mg/l to
0.0625 mg/l for MRSE. For MRSA biofilms, the MBC of
dalbavancin ranged from 1 mg/l to 4 mg/l, and from 2 mg/l
to 16 mg/l for MRSE. (Table 1, Fig. 1)
Discussion
The aim of this study was to investigate the activity of
dalbavancin against MRSA and MRSE growing in biofilms.
The advantages of dalbavancin include its weekly dosing reg-
imen and its high efficacy against gram-positive prokaryotes.
In a study published by Raad et al., the efficacy of dalbavancin
(one biweekly dose) compared with a 14-day course of van-
comycin (twice a day) in patients with catheter-related blood-
stream infection was evaluated [8]. The study showed
dalbavancin to have a higher overall success rate compared
to vancomycin. As a result it was hypothesized that due to the
high plasma concentrations of dalbavancin, its penetration in-
to biofilms could be significantly higher than that of vanco-
mycin. However, until this point, in-vitro activity of
dalbavancin against biofilms has not been evaluated [8].
From the results of this study, dalbavancin shows in-vitro
activity against biofilms with MRSA and MRSE in concen-
trations between 1 and 16 mg/l, which are concentrations eas-
ily reached in vivo, as mean plasma concentrations have been
shown to be > 35 mg/l for 7 days after one dose of 1,000 mg
[6]. Another study conducted by Baldoni et al. investigated
the activity of dalbavancin against planktonic and biofilm
MRSA in a foreign-body infection model in guinea pigs.
Dalbavancin led to a reduction of planktonic MRSA in cage
Table 1 Comparison ofMICs andMBCs for MRSA (μMBC= 1.80 mg/l;
SD MBC = ± 0.919 mg/l) and MRSE (μ MBC = 12.2 mg/l; SD MBC = ±
8.967 mg/l) bloodstream isolates
Isolate MRSA MRSE
MIC (mg/l) MBC (mg/l) MIC (mg/l) MBC(mg/l)
1 0.064 4 0.023 8
2 0.064 2 0.0625 8
3 0.032 2 0.032 16
4 0.032 2 0.023 4
5 0.047 1 0.047 2
6 0.032 2 0.023 4
7 0.0312 1 0.0625 16
8 0.064 2 0.047 16
9 0.0312 1 0.032 16
10 0.0312 1 0.032 16
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fluid, but failed to eradicate biofilm MRSA from cages [7].
Only when dalbavancin was combined with rifampicin could
reduction of biofilm MRSA be observed [7]. We suspect this
finding to be due to higher protein binding in the in-vivo
model, as the intraperitoneally applied concentrations of
dalbavancin resemble the concentrations used in our in-vitro
model [7]. Furthermore, metabolic processes after intraperito-
neal application play a crucial role in the in-vivo model.
Despite the advantages of subcutaneous animal foreign body
models, they also have some limitations. In pharmacokinetic
studies, differences in metabolic processes in small animals
compared to humans have to be taken into account [11]. To
further understand these findings, foreign body models with
intravenous application of dalbavancin are needed. Focusing
on in-vitro effects of dalbavancin, we observed previously
undescribed properties of this antimicrobial agent. In the test
runs performed prior to our experiment, we dissolved 500 mg
of dalbavancin in 25 ml aqua bidestillata and 5% glucose
(50 mg/ml) as described in the package information leaflet,
and performed the same biofilm assay as described above;
however, no reduction of biofilm could be observed. The
OD650 was even higher in the wells filled with the highest
dalbavancin concentrations, which made us revise our meth-
od. Comparing our results of dalbavancin in TSB with
our pretests of dalbavancin in glucose, we concluded
that in-vitro biofilm growth of MRSA and MRSE might
be enhanced by glucose even when combined with
dalbavancin. This effect is very likely to apply to the
in-vitro model only, as glucose is metabolized in vivo
after intravenous administration. We conclude that
dalbavancin successfully reduced biofilms in vitro at
concentrations which can be easily obtained in vivo,
which substantiates the previously published findings
that dalbavancin might have considerable potential as a
drug in medical device infections, for which it is cur-
rently not approved [6]. In conclusion, because of the
activity of dalbavancin on MRSA and MRSE biofilms
demonstrated in this study, we recommend further stud-
ies on the activity and efficacy of dalbavancin in in-
vivo models with medical device associated infections,
as a biweekly dosing regimen could not only reduce
healthcare costs, but also improve patients’ quality of
life.
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Fig. 1 Mean OD620 for MRSA (μOD620 = 0.579; SD OD620 = ± 0.186)
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